Search Within

Gilles Andre Salles

Formats
  1. Meeting Abstract (181)
  2. Journal Article (74)
  3. Research Letter (18)
  4. Review (17)
  5. Editorial (5)
  6. Correspondence (3)
  7. Conference Paper (2)
  8. Guidelines (2)
  9. Book Section (1)
Groups
  1. Department of Medicine (303)
  2. Hematologic Malignancies, Division of (303)
  3. Center for Hematologic Malignancies (163)
  4. Lymphoma (159)
  5. Survivorship Research (115)
  6. Graduate Medical Education (106)

More Groups

People
  1. Maria Palomba (108)
  2. Andrew Zelenetz (74)
  3. Lorenzo Falchi (64)
  4. Anita Kumar (63)
  5. Gunjan Shah (61)
  6. Miguel-Angel Perales (59)

More People

Years
  1. 2025 (20)
  2. 2024 (67)
  3. 2023 (97)
  4. 2022 (69)
  5. 2021 (44)
  6. 2020 (6)
Publications
  1. Blood (126)
  2. Hematological Oncology (28)
  3. Journal of Clinical Oncology (17)
  4. Blood Advances (16)
  5. Haematologica (14)
  6. British Journal of Haematology (9)

More Publications

Publishers
  1. American Society of Hematology (143)
  2. Wiley Blackwell (30)
  3. Elsevier Inc. (20)
  4. American Society of Clinical Oncology (17)
  5. Ferrata Storti Foundation (14)
  6. Nature Publishing Group (14)

More Publishers

Results (303)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Interim positron emission tomography during frontline chemoimmunotherapy for follicular lymphoma
    Journal Article

    Merryman, R. W.; Michaud, L.; Redd, R.; Mondello, P.; Park, H.; Spilberg, G.; Robertson, M.; Taranto, E.; Ahmed, G.; Chase, M.; more...
    HemaSphere (2023)

    Fulltext@MSK | Save
  • Bispecific antibodies for the treatment of B-cell lymphoma: Promises, unknowns, and opportunities
    Review

    Falchi, L.; Vardhana, S. A.; Salles, G. A.
    Blood (2023)

    Fulltext@MSK | Save
  • Application of the Lugano classification for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The PRoLoG consensus initiative (Part 1-Clinical)
    Journal Article

    Ricard, F.; Cheson, B.; Barrington, S.; Trotman, J.; Schmid, A.; Brueggenwerth, G.; Salles, G.; Schwartz, L.; Goldmacher, G.; Jarecha, R.; more...
    Journal of Nuclear Medicine (2023)

    Fulltext@MSK | Save
  • High-dose cytarabine and autologous stem-cell transplantation in mantle cell lymphoma: Long-term follow-up of the randomized Mantle Cell Lymphoma Younger trial of the European Mantle Cell Lymphoma Network
    Journal Article

    Hermine, O.; Jiang, L.; Walewski, J.; Bosly, A.; Thieblemont, C.; Szymczyk, M.; Pott, C.; Salles, G.; Feugier, P.; Hübel, K.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Higher levels of circulating exhausted T-cells at pre- and post-infusion negatively associated with clinical efficacy in tisagenlecleucel (Tisa-cel) treated relapsed/refractory large B-cell lymphoma (r/r LBCL) patients (pts) in JULIET trial
    Meeting Abstract

    Jäger, U.; Han, X.; Germano, D.; Quinn, D.; Gaddis, D.; Masood, A.; Mulvey, T.; Mataraza, J.; Bishop, M. R.; Salles, G.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • MSK-ACCESS Heme: A cell-free DNA next-generation sequencing assay to identify somatic alterations in patients with lymphoma
    Meeting Abstract

    DiNapoli, S. E.; Spence, C.; Gedvilaite, E.; Bowman, A.; Diosdado, M.; Razumova, A.; Tsui, D.; Salles, G. A.; Batlevi, C.; von Keudell, G.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Ttafasitamab plus lenalidomide (TAFA+LEN) versus pola-BR, r2, and CAR-T in non-transplant eligible (NTE) relapsed/refractory (r/r) DLBCL: A post hoc analysis of the RE-MIND2 study comparing multiple cohort-balancing approaches
    Meeting Abstract

    Córdoba, R.; Zinzani, P. L.; Joffe, E.; Yoon, D. H.; Peters, A.; Waltl, E. E.; Alvero, C.; Sabatelli, L.; Salles, G.; Nowakowski, G. S.
    Value in Health (2022)

    Fulltext@MSK | Save
  • L-MIND: Safety and efficacy of tafasitamab in patients with relapsed/refractory diffuse large B-cell lymphoma on treatment for at least 2 years
    Meeting Abstract

    Duell, J.; Jurczak, W.; Liberati, A. M.; Halka, J.; Carbó, E. P.; Abrisqueta, P.; Maddocks, K. J.; Dreyling, M.; Rosenwald, A.; Bakuli, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Subgroup analysis in RE-MIND2: An observational, retrospective cohort study of tafasitamab + lenalidomide versus systemic therapies in patients with relapsed/refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Nowakowski, G.; Yoon, D. H.; Joffe, E.; Zinzani, P. L.; Sabatelli, L.; Waltl, E. E.; Alvero, C. G.; Hess, G.; Riedell, P.; Kim, K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from the phase III POLARIX study
    Meeting Abstract

    Flowers, C.; Tilly, H.; Morschhauser, F.; Sehn, L. H.; Friedberg, J. W.; Trněný M.; Sharman, J. P.; Herbaux, C.; Burke, J. M.; Matasar, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save